Cytek Biosciences Stock Net Income
| CTKB Stock | USD 6.69 0.14 2.14% |
Cytek Biosciences fundamentals help investors to digest information that contributes to Cytek Biosciences' financial success or failures. It also enables traders to predict the movement of Cytek Stock. The fundamental analysis module provides a way to measure Cytek Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytek Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.9 M | -13.2 M | |
| Net Income Applicable To Common Shares | 3 M | 3.1 M | |
| Net Loss | -12.1 M | -11.5 M | |
| Net Loss | (0.09) | (0.09) | |
| Net Income Per E B T | 0.77 | 0.95 |
Cytek | Net Income |
Cytek Biosciences Company Net Income Analysis
Cytek Biosciences' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cytek Biosciences Net Income | (12.15 M) |
Most of Cytek Biosciences' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytek Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cytek Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cytek Biosciences is extremely important. It helps to project a fair market value of Cytek Stock properly, considering its historical fundamentals such as Net Income. Since Cytek Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytek Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytek Biosciences' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cytek Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cytek Biosciences reported net income of (12.15 Million). This is 103.56% lower than that of the Health Care Equipment & Supplies sector and 105.1% lower than that of the Health Care industry. The net income for all United States stocks is 102.13% higher than that of the company.
Cytek Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytek Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytek Biosciences could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics of similar companies.Cytek Biosciences is currently under evaluation in net income category among its peers.
Cytek Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cytek Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cytek Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cytek Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cytek Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cytek Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cytek Biosciences' value.| Shares | Northern Trust Corp | 2024-09-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | Millennium Management Llc | 2024-06-30 | 946.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 804.3 K | Fmr Inc | 2024-09-30 | 667.1 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 631.5 K | Jpmorgan Chase & Co | 2024-06-30 | 608.4 K | Fidelity International Ltd | 2024-06-30 | 573.6 K | Principal Financial Group Inc | 2024-09-30 | 503.2 K | Blackrock Inc | 2024-06-30 | 17.1 M | Vanguard Group Inc | 2024-09-30 | 11.8 M |
Cytek Fundamentals
| Return On Equity | -0.0254 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 598.48 M | ||||
| Shares Outstanding | 128.81 M | ||||
| Shares Owned By Insiders | 8.84 % | ||||
| Shares Owned By Institutions | 59.02 % | ||||
| Number Of Shares Shorted | 4.2 M | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 4.28 X | ||||
| Revenue | 193.01 M | ||||
| Gross Profit | 100.97 M | ||||
| EBITDA | (4.41 M) | ||||
| Net Income | (12.15 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 14.14 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.97 X | ||||
| Cash Flow From Operations | 5.28 M | ||||
| Short Ratio | 8.89 X | ||||
| Earnings Per Share | (0.08) X | ||||
| Target Price | 8.4 | ||||
| Number Of Employees | 645 | ||||
| Beta | 1.32 | ||||
| Market Capitalization | 861.75 M | ||||
| Total Asset | 494.46 M | ||||
| Retained Earnings | (29.18 M) | ||||
| Working Capital | 335.83 M | ||||
| Net Asset | 494.46 M |
About Cytek Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytek Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytek Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytek Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Cytek Biosciences Piotroski F Score and Cytek Biosciences Altman Z Score analysis. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.08) | Revenue Per Share 1.527 | Quarterly Revenue Growth 0.073 | Return On Assets (0.03) |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.